fda tirzepatide compounding warning 2024 2025 'Compounded' weight-loss drugs are a growing problem for state regulators The FDA has strictly clarified

announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding In August 2025, Novo Nordisk cirrhosis , in combination with diet and exercise

Above a certain point, additional B6 provides no further benefit and begins to carry toxicity risk

Additionally, GLP-1 suppresses pancreatic exocrine secretion, a proposed mechanism linked to the development of pancreatitis [123]

From a supplement perspective, GLP-1 production naturally decreases with age, like many things in the body including stomach acid and collagen production

Check with your insurance provider, as many plans now cover FDA-approved weight loss injections like Wegovy and Zepbound